Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06149793 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint added 1 → 2 primary endpoints
See other at-risk trials from University of Minnesota

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Results posted: Sep 21, 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Enrollment target: 12 to 8
    • Primary endpoints revised (2)
    • Secondary endpoints: details revised at 1 of 1 entry
    v9
  3. Enrollment target: 8 to 12
    • Primary endpoints: 1 to 2
    • Secondary endpoints expanded, about 2 words
    v8
  4. Start date: Oct 16, 2023 to Jan 8, 2024
    • Primary completion date: Dec 23, 2025 to Jun 3, 2025
    v7
  5. Primary completion date changed from estimate of Dec 31, 2025 to Dec 23, 2025
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    • Start date: Dec 30, 2023 to Oct 16, 2023
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Lead sponsor: Amir Moheet to University of Minnesota
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 15 to confirmed 8
    • Site details revised
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  4. Study title shortened, about 12 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.
Trial Details
NCT Number NCT06149793
Lead Sponsor University of Minnesota
Conditions
(from sponsor)		 Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Related terms Cystic Fibrosis
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov